PXDN

Across TCGA pan-cancer cohorts, PXDN mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PXDN data layer compared with 28 for mass-spec protein and 14 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PXDN mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PXDN expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where PXDN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.351	1.000	.002	30	view →
LUAD	OS	Median	All	0.770	0.926	.009	27	view →
GBM	DFS	Tertile	All	0.283	0.439	.028	6	view →
PDAC	OS	Tertile	II,III,IV	0.437	0.700	.027	6	view →
HNSC	DFS	Median	II,III,IV	0.974	0.895	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PXDN–CCRCC (DFS)

Open the CCRCC breakdown →